Health Technology

Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2023	JPY	USD
Revenue	4,027.47B	29,719.25M
Gross Profit	2,240.96B	16,536.34M
Operating income	610,329M	4,503.69M
Income before tax	383,720M	2,831.51M
Net income	317,017M	2,339.30M
EBITDA	1,274.72B	9,406.38M
Diluted EPS	201.93	1.49
Dividends Per Share	180	1.32
Total Assets	13,957.75B	104,874.52M
Total liabilities	7,603.08B	57,127.35M
Total equity	6,354.12B	47,743.04M
Operating cash flow	877,217M	6,473.09M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Revenue	2,097.22B	3,291.18B	3,197.81B	3,569.00B	4,027.47B
Gross Profit	1,275.55B	1,789.37B	1,798.37B	2,043.63B	2,240.96B
Operating income	218,686M	302,612M	447,610M	610,496M	610,329M
Income before tax	127,612M	-60,754M	366,159M	317,938M	383,720M
Net income	135,192M	44,241M	376,005M	230,059M	317,017M
EBITDA	466,377M	886,261M	1,007.28B	1,193.64B	1,274.72B
Diluted EPS	139.82	28.24	238.95	145.86	201.93
Dividends Per Share	180	180	180	180	180
Total Assets	13,792.77B	12,821.09B	12,912.29B	13,178.01B	13,957.75B
Total liabilities	8,606.78B	8,093.60B	7,735.11B	7,494.49B	7,603.08B
Total equity	5,181.98B	4,723.48B	5,173.03B	5,683.01B	6,354.12B
Operating cash flow	302,609M	555,410M	905,073M	1,021.21B	877,217M

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Revenue	18,911.85M	30,270.54M	30,151.70M	31,760.44M	29,719.25M
Gross Profit	11,502.42M	16,457.72M	16,956.61M	18,186.20M	16,536.34M
Operating income	1,972.01M	2,783.25M	4,220.44M	5,432.77M	4,503.69M
Income before tax	1,150.74M	-558.78M	3,452.46M	2,829.31M	2,831.51M
Net income	1,219.10M	406.90M	3,545.29M	2,047.28M	2,339.30M
EBITDA	4,205.58M	8,151.34M	9,497.50M	10,622.21M	9,406.38M
Diluted EPS	1.26	0.25	2.25	1.29	1.49
Dividends Per Share	1.62	1.65	1.69	1.60	1.32
Total Assets	124,612.85M	118,763.31M	116,853.33M	108,572.75M	104,874.52M
Total liabilities	77,759.25M	74,972.05M	70,001.05M	61,746.62M	57,127.35M
Total equity	46,817.41M	43,754.18M	46,814.81M	46,821.99M	47,743.04M
Operating cash flow	2,728.79M	5,108.35M	8,533.80M	9,087.77M	6,473.09M

Valuation Measures

Mar 2023
PER	21.29
ROA	2.33%
ROE	5.26%
Operating margin	15.15%
Profit margin	7.87%

Key executives

President, CEO & Representative Director: Christophe Weber
Chief Financial Officer & Director: Constantine Saroukos
Director, President-Research & Development: Andrew S. Plump
Chief Medical & Scientific Officer: Michael E. Mendelsohn
Chief Accounting Officer & Corporate Controller: Norimasa Takeda

Shareholders

Nomura Asset Management Co., Ltd. (4.2%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
The Vanguard Group, Inc. (2.5%)
Nikko Asset Management Co., Ltd. (2.0%)
Daiwa Asset Management Co. Ltd. (1.9%)
BlackRock Fund Advisors (1.8%)
Nippon Life Insurance Co. (1.8%)
Capital Research & Management Co. (Global Investors) (1.6%)
Norges Bank Investment Management (1.5%)
Capital International Ltd. (1.3%)

Contact Details

Website:http://www.takeda.co.jp
Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
Phone: +81.6.6204.2111

Related Companies

Takeda Pharmaceutical Co Ltd /Asker Pharma Manufacturing Ops/
Nimbus Lakshmi, Inc.
Takeda Digital Ventures
Takeda Pharmaceutical Employee Long Term Incentive Plan
Takeda Dunboyne Biologics Ltd.
Plasmaspendedienst GmbH
Takeda Belgium NV
Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
Adaptate Biotherapeutics Ltd.
Takeda Re Insurance AG
Plasmapunkt Favoriten GmbH
Takeda Malaysia Sdn. Bhd.
Takeda Pharmaceutical Co. Ltd. /Latam Bus/
Takeda Oranienburg Real Estate GmbH & Co. KG
Pvp Biologics, Inc.
Maverick Therapeutics, Inc.
Gammadelta Therapeutics Ltd.
Takeda Pharmaceutical Director Incentive Plan
Takeda Pharmaceutical Employee Incentive Plan
Oy Leiras Takeda Pharmaceuticals AB
Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
Takeda Pharma AB
Takeda Development Center Americas, Inc.
Takeda Ukraine LLC
Takeda Pharmaceuticals Taiwan Ltd.
Takeda SRL
Takeda Hellas SA
Takeda Christiaens SCA/CVA
Takeda Belgium SCA/CVA
Takeda Vaccines Pte Ltd.

Competitors

AstraZeneca PLC
Grifols, S.A. Class A
Green Cross Corporation
Amgen Inc.
CSL Limited
Novo Nordisk A/S Class B
Amicus Therapeutics, Inc.
Pharming Group NV
Protalix Biotherapeutics, Inc.
ADMA Biologics, Inc.
Novartis AG
Pfizer Inc.
Johnson & Johnson
Sanofi
Mochida Pharmaceutical Co., Ltd.
AbbVie, Inc.
Bristol-Myers Squibb Company
Organon & Co.
Merck & Co., Inc.
Bayer AG
Roche Holding Ltd Dividend Right Cert.
Karyopharm Therapeutics, Inc.
Swedish Orphan Biovitrum AB
UCB S.A.
Merck KGaA
JCR Pharmaceuticals Co., Ltd.
Supernus Pharmaceuticals, Inc.
Oncopeptides AB
BioCryst Pharmaceuticals, Inc.
ISU Abxis Co., Ltd.

Last Updated on 26 May, 2023